HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-
poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has …

The Met receptor tyrosine kinase (RTK) regulates several distinct biological processes,
including cell scatter, cell invasion, cell survival and epithelial remodeling. MET is …

Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-
free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed …

The past decade of research into HER2‐overexpressing breast cancer has provided
significant insight into the mechanisms by which HER2 signaling drives tumor progression …

Purpose: To evaluate cMET (mesenchymal–epithelial transition factor gene) and phospho-
cMET (p-cMET) levels in breast cancer subtypes and its impact on survival outcomes …

Background: To investigate whether copy number gain of MET or hepatocyte growth factor
(HGF) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC) …

Understanding the signaling pathways that drive aggressive breast cancers is critical to the
development of effective therapeutics. The oncogene MET is associated with decreased …

The anti-HER receptor antibodies cetuximab, trastuzumab, and pertuzumab are used widely
in clinic to treat metastatic cancer. However, activation of the extensive crosstalk among the …

Recent findings suggest the involvement of the MET oncogene, encoding the tyrosine
kinase receptor for hepatocyte growth factor, in the onset and progression of basal-like …

The HGF/Met signaling pathway is deregulated in majority of cancers and is associated with
poor prognosis in breast cancer. Delphinidin, present in pigmented fruits and vegetables …